Publications

Found 43 results
Filters: Keyword is Antibodies, Neutralizing  [Clear All Filters]
2013
Kulp DW, Schief WR.  2013.  Advances in structure-based vaccine design.. Curr Opin Virol. 3(3):322-31.
Crispin M, Bowden TA.  2013.  Antibodies expose multiple weaknesses in the glycan shield of HIV.. Nat Struct Mol Biol. 20(7):771-2.
Gavrilyuk J, Ban H, Uehara H, Sirk SJ, Saye-Francisco K, Cuevas A, Zablowsky E, Oza A, Seaman MS, Burton DR et al..  2013.  Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG.. J Virol. 87(9):4985-93.
Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, Buckler-White A, Seaman M, Piatak M, Lifson JD et al..  2013.  Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia.. Nature. 503(7475):277-80.
Ota T, Doyle-Cooper C, Cooper AB, Doores KJ, Aoki-Ota M, Le K, Schief WR, Wyatt RT, Burton DR, Nemazee D.  2013.  B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates.. J Immunol. 191(6):3179-85.
Lyumkis D, Julien J-P, de Val N, Cupo A, Potter CS, Klasse P-J, Burton DR, Sanders RW, Moore JP, Carragher B et al..  2013.  Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer.. Science. 342(6165):1484-90.
Doyle-Cooper C, Hudson KE, Cooper AB, Ota T, Skog P, Dawson PE, Zwick MB, Schief WR, Burton DR, Nemazee D.  2013.  Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10.. J Immunol. 191(6):3186-91.
Klasse P J, Depetris RS, Pejchal R, Julien J-P, Khayat R, Lee J H, Marozsan AJ, Cupo A, Cocco N, Korzun J et al..  2013.  Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein.. J Virol. 87(17):9873-85.
Zhou T, Zhu J, Wu X, Moquin S, Zhang B, Acharya P, Georgiev IS, Altae-Tran HR, Chuang G-Y, M Joyce G et al..  2013.  Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies.. Immunity. 39(2):245-58.
Chuang G-Y, Acharya P, Schmidt SD, Yang Y, Louder MK, Zhou T, Kwon Y D, Pancera M, Bailer RT, Doria-Rose NA et al..  2013.  Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains.. J Virol. 87(18):10047-58.
Sok D, Moldt B, Burton DR.  2013.  SnapShot: broadly neutralizing antibodies.. Cell. 155(3):728-728.e1.
Pancera M, Shahzad-ul-Hussan S, Doria-Rose NA, McLellan JS, Bailer RT, Dai K, Loesgen S, Louder MK, Staupe RP, Yang Y et al..  2013.  Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.. Nat Struct Mol Biol. 20(7):804-13.
2012
Ota T, Doyle-Cooper C, Cooper AB, Huber M, Falkowska E, Doores KJ, Hangartner L, Le K, Sok D, Jardine J et al..  2012.  Anti-HIV B Cell lines as candidate vaccine biosensors.. J Immunol. 189(10):4816-24.
Feng Y, McKee K, Tran K, O'Dell S, Schmidt SD, Phogat A, Forsell MN, Karlsson Hedestam GB, Mascola JR, Wyatt RT.  2012.  Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.. J Biol Chem. 287(8):5673-86.
Dosenovic P, Soldemo M, Scholz JL, O'Dell S, Grasset EK, Pelletier N, Karlsson MCI, Mascola JR, Wyatt RT, Cancro MP et al..  2012.  BLyS-mediated modulation of naive B cell subsets impacts HIV Env-induced antibody responses.. J Immunol. 188(12):6018-26.
Burton DR, Poignard P, Stanfield RL, Wilson IA.  2012.  Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses.. Science. 337(6091):183-6.
Mouquet H, Scharf L, Euler Z, Liu Y, Eden C, Scheid JF, Halper-Stromberg A, Gnanapragasam PNP, Spencer DIR, Seaman MS et al..  2012.  Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies.. Proc Natl Acad Sci U S A. 109(47):E3268-77.
Cheng C, Wang L, Wang LS, Gall JGD, Nason M, Schwartz RM, McElrath JM, DeRosa SC, Hural J, Corey L et al..  2012.  Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination.. PLoS One. 7(4):e33969.

Pages